Botulinum toxin–induced blepharoptosis: Anatomy, etiology, prevention, and therapeutic options

BACKGROUND: Botulinum toxin A (BoNT‐A) has grown tremendously in aesthetic dermatology since 2002 when the United States Food and Drug Administration (FDA) first approved its use for treating moderate‐to‐severe glabellar lines. Blepharoptosis, due to local spread of toxin, is a reported side effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Nestor, Mark S., Han, Haowei, Gade, Anita, Fischer, Daniel, Saban, Yves, Polselli, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Neurotoxins
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290925/
https://www.ncbi.nlm.nih.gov/pubmed/34378298
http://dx.doi.org/10.1111/jocd.14361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290925/
https://www.ncbi.nlm.nih.gov/pubmed/34378298
http://dx.doi.org/10.1111/jocd.14361

Ejemplares similares